Company
Telix Pharmaceuticals Ltd (TLX)
Standardized SEC financial data for Telix Pharmaceuticals Ltd — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0002007191 · NASDAQ · Pharmaceutical Preparations.
Gross margin
53.0%
Net margin
-0.9%
Revenue growth (YoY)
55.6%
Return on equity
-1.7%
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $333.0M | $516.6M | $803.8M |
| Cost of revenue | $123.4M | $180.4M | $377.4M |
| Gross profit | $209.5M | $336.2M |
Balance sheet
| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Goodwill | — | — | $66.6M | $199.0M |
| Total assets | — | $277.3M | $940.4M | $1.16B |
Get TLX data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/TLX/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/TLX/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"